Fusion proteins containing the amino-terminal domain of human p14
Introduction
Human p14 ARF , one of the alternative products of the INK4a/ARF tumour-suppressor locus (Sharpless and DePinho, 1999; Sherr, 2001) , is a small basic protein whose major documented function is to bind directly to MDM2 and inhibit its ubiquitin ligase activity (Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998; Honda and Yasuda, 1999; Midgley et al., 2000) . The principal role of MDM2 is to counterbalance the p53 tumour suppressor, by targeting it for ubiquitylation and degradation, by blocking its transcriptional activity, and by promoting its nuclear export (Ashcroft and Vousden, 1999) . Elevated expression of ARF therefore results in the stabilization of p53 and activation of p53-responsive genes, including MDM2. Thus, the three proteins engage in a regulatory circuit in which p53 activates transcription of its negative regulator, MDM2, but represses that of its positive regulator, ARF (Sharpless and DePinho, 1999; Sherr, 2001) . Such a mechanism can potentially set an upper limit on p53 activity.
Expression of ARF can be induced by members of the E2F family of transcription factors (DeGregori et al., 1997; Bates et al., 1998; Robertson and Jones, 1998; Dimri et al., 2000; Parisi et al., 2002) and, as the latter are negatively regulated by the retinoblastoma gene product (pRb), ARF provides a link between the pRb and p53 pathways (Sharpless and DePinho, 1999; Sherr, 2001) . Agents that inactivate pRb will inevitably activate p53 via ARF, but again this effect may be self-limiting as p14 ARF has been shown to bind to and downregulate E2F1 (Eymin et al., 2001; Martelli et al., 2001) .
Normal human cells contain low levels of p14 ARF that are barely detectable with currently available reagents, but the protein becomes detectable if p53 function is ablated, or upon ectopic expression of E2F1 Zhang and Xiong, 1999; Lindstro¨m et al., 2000; Llanos et al., 2001) . Most experiments are therefore conducted under conditions of overexpression. When p14 ARF becomes detectable, it is predominantly localized in the nucleolus Zhang and Xiong, 1999; Lindstro¨m et al., 2000) , leading to the assumption that it must also function in the nucleolus. In some circumstances, elevated levels of ARF cause MDM2, which is normally nucleoplasmic, to relocate to the nucleolus (Tao and Levine, 1999; Weber et al., 1999; Lohrum et al., 2000; Rizos et al., 2000; Weber et al., 2000) . However, this is not universal and is not essential for the ability of ARF to stabilize p53 (Lin and Lowe, 2001; Llanos et al., 2001; Korgaonkar et al., 2002) . For example, we found that a chimaeric protein containing the amino-terminal 29 residues of ARF fused to green fluorescent protein (GFP/2-29) is able to upregulate MDM2 and p53 despite being excluded from the nucleolus (Llanos et al., 2001) .
In these studies, we noted that the levels of GFP/2-29 in transfected cells were generally lower than those of the GFP control or fusion proteins containing more extensive regions of ARF. Here we investigate the effects of subcellular localization on the turnover of ARF fusion proteins. The stability of GFP/2-29 can be enhanced by redirecting it to the nucleolus, by depleting the cells of MDM2, or by inhibiting proteasome function, suggesting a model in which ARF associates with MDM2 in the nucleoplasm but is consequently subject to rapid turnover. Any ARF that is deposited in the nucleolus will be protected from these effects and remain available over a longer time frame.
Results

Nucleolar localization is not required for ARF function
In transiently transfected U20S cells, the GFP/2-29 ARF fusion protein is localized primarily in the nucleoplasm, with little staining of the nucleolus (Llanos et al., 2001) . However, it can be redirected to the nucleolus by the addition of a basic motif (3 Â NLS) comprising three copies of the nuclear localization signal from SV40 large T antigen (Figure 1a) . When the transfected cells were compared by immunoblotting, we noted that the non-nucleolar forms of the protein were present at lower levels than the nucleolar forms (Figure 1b) , irrespective of the cell background. As the plasmids had the same regulatory sequences, the most likely explanation was that non-nucleolar forms of the protein were less stable. We therefore decided to compare the half-lives by generating stable cell lines in which the various forms of ARF were expressed from a regulatable promoter.
Half-life of p14 ARF in human cells
To control for the influence that GFP might have on the stability of the fusion proteins, we first determined the half-life of p14 ARF in NARF cells, which are derivatives of the U20S cell line that express p14
ARF from an IPTGregulated promoter . After induction, the cells were treated with cycloheximide and the turnover of ARF was monitored by immunoblotting of cell lysates harvested at intervals up to 8 h (Figure 2a ). Under these conditions, the calculated half-life of p14 ARF was 70 min. We additionally assessed the half-life of p14 ARF in NARF cells transfected with a vector that encodes the HPV16 E6 protein (Llanos et al., 2001) . E6 promotes the degradation of p53 via the E6AP ubiquitin ligase (Scheffner et al., 1993) , and consequently the NARF þ E6 cells expressed reduced levels of p53 and MDM2 (Figure 2b ). Under these conditions, the halflife of the inducible p14 ARF was increased by approximately 2.5-fold.
Addition of the 3 Â NLS motif increases the half-life of GFP/2-29
In preliminary experiments, we found it difficult to establish equivalent IPTG-regulated cell lines expressing the GFP/2-29 fusion protein, because the low levels of protein proved difficult to visualize. We therefore used a tetracycline-regulated system which provided higher basal and inducible levels of expression. Clonal lines of U20S cells were established which expressed the GFP/2-132, GFP/2-29, and GFP/2-29 þ 3 Â NLS versions of ARF upon addition of doxycycline (Figure 3a) . Immunoblotting with GFP antibody confirmed that fusion proteins of the expected size were being expressed at comparable levels. In each case, addition of doxycycline resulted in upregulation of p53 (Figure 3a) , confirming previous evidence that the ARF fusion proteins bind MDM2 and are functional in p53 stabilization assays (Llanos et al., 2001) . The fusion proteins also showed the expected subcellular distributions with GFP/2-132 and GFP/2-29 þ 3 Â NLS predominantly nucleolar, whereas GFP/2-29 was effectively excluded from the nucleolus ( Figure 3b ).
As we selected for maximal expression of GFP/2-29, the distinction between the steady-state levels of the various fusion proteins is less obvious in the clonal lines than in the transient transfectants in Figure 1 . Nevertheless, when the inducible cells were used to monitor protein turnover, following addition of cycloheximide, the differences became quite marked (Figure 3c ). The GFP/2-132 protein had a projected half-life of 10 h, considerably longer than authentic ARF. This presumably reflects the stabilizing influence of GFP; in equivalent U20S cells expressing GFP alone, the turnover was imperceptible during the 8-h time course. In contrast, the fusion protein containing residues 2-29 of ARF was much less stable, with a half-life of approximately 2.5 h. Addition of the 3 Â NLS motif restored the stability of the fusion protein. Indeed, the GFP/2-29 þ 3 Â NLS construct appeared more stable than GFP/2-132. This would be consistent with the idea that nucleolar localization confers stability on these fusion proteins. In previous studies, we have shown that, while GFP/2-132 is predominantly nucleolar, a significant fraction remains nucleoplasmic (Llanos et al., 2001) . The addition of the 3 Â NLS motif may accentuate the association with the nucleolus.
Instability of GFP/2-29 is dependent on MDM2
These data implied that the amino-terminal domain of ARF could effectively target GFP for degradation. As the turnover of the fusion protein was blocked by addition of the proteasome inhibitor MG132 (Figure 4) , we speculated that the instability of GFP/2-29 could reflect its capacity to associate with MDM2, a recognized E3 ubiquitin ligase that undergoes self-ubiquitylaton (Honda et al., 1997; Honda and Yasuda, 1999; Fang et al., 2000; Honda and Yasuda, 2000; Midgley et al., 2000) . If true, then reducing the expression or activity of MDM2 in the cell should increase the stability of the fusion protein. To address this possibility, we used the HPV E6 protein to promote the destruction of p53, which indirectly reduces the expression of MDM2 (Figure 5a ). This caused a noticeable increase in the levels of GFP/2-29 following addition of doxycycline (Figure 5a) , and in the half-life of the protein as measured over an 8-h time course (Figure 5b ). As this effect paralleled the stabilization of full-length p14 ARF by HPV E6 (see Figure 2) , we confirmed that the full-length protein expressed in NARF cells is also (Figure 4b) .
To substantiate the role of MDM2 in the turnover of ARF, cells expressing inducible GFP/2-29 were transfected with plasmids encoding MDMX, an MDM2-related protein that can bind to MDM2 and interfere with its function. As a control, we used a mutant form of MDMX (MDMXR-) that lacks the C-terminal ring finger and is therefore unable to associate with MDM2 (Jackson and Berberich, 2000; Migliorini et al., 2002) . Immunoblotting confirmed that the wild-type and mutant proteins were expressed at equivalent levels ( Figure 6a ). MDMX caused significant stabilization of GFP/2-29, whereas the MDMXR-mutant had no effect on the turnover of the fusion protein ( Figure 6b) .
As an alternative strategy, we used short interfering RNA (siRNA) oligomers to specifically reduce the levels of MDM2. The sequences chosen were identical to those described in a recent publication , and as reported caused a substantial reduction of MDM2 levels following transient transfection into parental U20S cells or derivatives expressing inducible ARF (Figure 7a ; additional data not shown). At 24 h post transfection, the MDM2 siRNA caused a significant stabilization of GFP/2-29 over an 8-h time period (Figure 7b ), in line with the results obtained using HPV E6 and MDMX.
Discussion
A motivation for this study was our belief that p14 ARF normally functions in the nucleoplasm, where it can (Llanos et al., 2001; Clark et al., 2002) . These conclusions were based on cell fractionation experiments and on the construction of functional versions of ARF, such as GFP/2-29, that are excluded from the nucleolus. Moreover, we recently found that the chicken homologue of ARF, which comprises only 60 amino acids, retains the ability to bind MDM2 and to stabilize p53 in chick cells without being confined to the nucleolus (Kim et al., 2003; Kim and Peters, unpublished observations) . Why then do the mammalian ARF proteins show such a distinctive concentration in the nucleolus when visualized by immunofluorescence?
The results we present here offer a partial explanation. By generating U20S-based cell lines in which the various forms of ARF can be conditionally expressed, we show that non-nucleolar forms of human ARF are inherently unstable. Redirecting GFP/2-29 to the nucleolus by adding the 3 Â NLS motif dramatically stabilizes the fusion protein. Thus, nucleolar localization could be a means of storing and protecting ARF, or alternatively of depositing excess ARF out of harm's way.
At face value, our data also indicate that residues 2-29 of human ARF can cause the proteasome-mediated destruction of a stable protein such as GFP. This effect is in part dependent on the presence and function of MDM2, as it can be mitigated by HPV E6, MDMX, and siRNA against MDM2. As multiple domains in the amino-terminal region of ARF can interact directly with MDM2 (Lohrum et al., 2000; Midgley et al., 2000; Weber et al., 2000; Bothner et al., 2001; Llanos et al., 2001; Clark et al., 2002) , it is tempting to attribute the instability of GFP/2-29 to the ubiquitin ligase activity of MDM2. Three scenarios can be envisaged. In the first, the ARF sequences provide a docking site that converts GFP into a substrate for ubiquitylation by MDM2. Under normal circumstances, p14
ARF itself could only be ubiquitylated on the amino-terminal methionine, as it has no lysine residues, and we have been unable to detect ubiquitylated forms of GFP/2-29 using approaches that reveal in vivo ubiquitylation of p53 (not shown). In the second, the GFP/2-29 fusion protein is destroyed as an indirect consequence of its association with MDM2. Although ARF inhibits the ubiquitin ligase activity of MDM2 in vitro (Honda and Yasuda, 1999; Midgley et al., 2000) , p14
ARF can apparently block polyubiquitylation of p53 in vivo without affecting the self-ubiquitylation of MDM2 (Xirodimas et al., 2001 ). In the third scenario, delivery to the proteasome by MDM2 could occur without any requirement for ubiquitylation (Verma and Deshaies, 2000; Orlowski and Wilk, 2003) analogous to the MDM2-mediated turnover of p21 CIP1 . Irrespective of ubiquitylation, the 'guilt by association' model has the appeal that it could also apply to authentic ARF and could explain why it is difficult to visualize p14 ARF in the nucleoplasm, where it would be vulnerable to MDM2-mediated degradation. Thus, in binding to MDM2 and blocking its E3 ligase activity towards p53, ARF is effectively committing suicide. Once associated with the nucleolus, p14 ARF would be protected from the proteasome and its turnover would be largely unaffected by the p53/MDM2 status of the cell. However, as nucleoli represent dynamic assemblies that dissociate in response to various forms of cellular stress, and at mitosis, we surmise that ARF will be destabilized in these circumstances (David-Pfeuty and Nouvian-Dooghe, 2002; Rubbi and Milner, 2003) .
It is not technically possible to address these issues in the context of authentic ARF as some of the motifs that appear to be responsible for nucleolar localization overlap with domains implicated in functional interactions with other proteins. Against this background, the concentration of ARF in the nucleolus has encouraged the view that ARF function depends on nucleolar localization (Weber et al., 1999 (Weber et al., , 2000 Zhang and Xiong, 1999; Lohrum et al., 2000; Rizos et al., 2000 Rizos et al., , 2001 Itahana et al., 2003; Sugimoto et al., 2003) . Depending on one's point of view, our data could be seen as consistent with such an interpretation. Thus, versions of ARF that are excluded from the nucleolus would score as 'hypomorphic' because they are less stable and therefore less able to elicit the experimental readouts of ARF function, such as induction of p53 and cell cycle arrest. However, these assays generally rely on overexpression and it is unclear how physiological levels of ARF relate to the amounts involved in experimental . After 24 h, cell lysates were processed for immunodetection of MDM2, p53, and MEK as indicated. (b) Cells expressing inducible GFP/2-29 were transfected with the siRNA against MDM2 and, following addition of doxycyline for 16 h, the turnover of GFP/2-29 was monitored over an 8-h time period settings. There is also a lack of consistency in what ARF is alleged to do to its binding partners in different contexts. In addition to MDM2, ectopic expression of ARF can apparently sequester E2F1, DP1, HIF1, and other assorted proteins in the nucleolus (Fatyol and Szalay, 2001; Karayan et al., 2001; Martelli et al., 2001; Datta et al., 2002) . Our findings imply that nucleolar localization should protect these targets from degradation by the proteasome, but the opposite outcome appears to apply in the case of E2F1 and DP1 (Martelli et al., 2001; Datta et al., 2002) . ARF has also been shown to promote the degradation of the nucleolar protein, B23 (Itahana et al., 2003) .
An alternative interpretation would be that ARF can act as an adaptor that destabilizes client proteins by bringing them into a proteasome-sensitive complex with MDM2. As ARF can interact with MDM2 through multiple domains (Clark et al., 2002) , it has the potential to use some of these domains to associate with other proteins. Importantly, we speculate that the functionally significant interactions of ARF take place in the nucleoplasm rather than the nucleolus and result in the formation of transient, unstable complexes.
Materials and methods
Plasmids
Derivatives of the pEGFP-C3 vector (Clontech) encoding the GFP/2-132, GFP/2-29, and GFP/2-29 þ 3 Â NLS ARF fusion proteins have been described (Llanos et al., 2001) . The relevant sequences were recovered by PCR and transferred into the Not1 site of pOPRSVI for IPTG-regulated expression using the LacSwitcht system (Stratagene), and into the pcDNA4/TO vector for tetracycline-inducible expression in the T-RExt system (Invitrogen). Plasmids encoding GFPtagged MDMX and MDMXR-were provided by Domenico Migliorini (Migliorini et al., 2002) .
Cell culture U20S cells and their derivatives were cultured at 371C in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% foetal calf serum (FCS). NARF cells expressing human p14
ARF from an IPTG-regulated promoter were maintained under hygromycin selection (50 mg/ml).
A derivative line was generated by transfection with pBABEpuro encoding HPV-16 E6 and selection in puromycin (1.25 mg/ml). Cells engineered for doxycyline-inducible expression were selected in blasticidin (10 mg/ml) and zeocin (100 mg/ ml). Cells transfected with the MDMX or MDMXR-plasmids were co-transfected with pBABEpuro and selected in puromycin.
SiRNA knockdown of MDM2
A duplex siRNA oligomer (5 0 -AAGCCAUUGCUUUUGAA-GUUA-3 0 ), designed to target human MDM2 mRNA, was obtained from Dharmacon (Lafayette, CO, USA) in the 2 0 -deprotected, desalted, and purified form. Parental U20S cells, NARF cells, and clones expressing tetracycline-inducible GFP/2-29 were plated at 1.4 Â 10 5 cells per well in six-well plates. After 24 h, the cells were transfected with 200 mM siRNA or buffer control using 4 ml oligofectamine per well in Opti-MEM1 with Glutamaxt (Invitrogen) and reduced serum. After 5 h, DMEM containing serum was added to give a final concentration of 10% serum. The cells were then processed for measurement of protein stability as described below.
Protein half-life assays
Cells were treated with either 1 mM IPTG or 5 mg/ml doxycycline for 16 h to induce the expression of the ARF fusion proteins. In some experiments, the cells were then treated with the proteasome inhibitor MG132 (10 mM) or solvent control (DMSO). Protein synthesis was blocked by addition of cycloheximide (20 mM) and cells were processed for immunoblotting after 0, 1, 2, 4, 6, and 8 h. Antibody binding was visualized using Amersham ECL reagents. Antibodies against GFP (3E1) and p14 ARF (4C6) were provided by the Cancer Research UK Monoclonal Antibody Production service. Human p53 was detected with the DO-1 monoclonal (Santa Cruz SC#6243), MDM2 with the 2A10 monoclonal antibody (Oncogene Science), and MEK1/2 with a polyclonal antibody (#9122) from New England Biolabs.
Immunofluorescence
The methods used for immunofluorescence were as described (Llanos et al., 2001) .
